Blood Product Supply

NCT07490314 | Completed

• 1 other identifier: 045.TRA.2020.D
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Data about the links between Coronavirus disease 2019(COVID-19) and the safety of blood products during the pandemic is inadequate. During the COVID-19 pandemic, high volumes of patients receiving blood products due to post-terminal surgical complications depleted stores for the entire hospital, resulting in surgeons unable to acquire emergent blood products. Data from this study can be used to develop a policy on how to handle blood shortage issues during this and future pandemics. Also, this data can be used to determine future policies on use of blood products from COVID-19-positive donors.

Conditions

COVID-19

Outcome Measures

Primary Outcomes (1)

• Time frame

  Dates of inadequate or delayed blood products for emergent cases during the timeframe of the COVID-19 pandemic (March 2020 to March 2021) to be compared relative to number of days or cases where no shortages were noted

  1 year

Study Arms (1)

future policies on use of blood products from COVID-19-positive donors

Data from this study can be used to develop a policy on how to handle blood shortage issues during this and future pandemics.

Other: Document delays and frequencies of inadequate blood products for emergent cases

Interventions

Document delays and frequencies of inadequate blood products for emergent cases OTHER

The COVID-19 pandemic is contributing to delays in blood product acquisition and inadequate blood product supplies for emergent cases in hospitals

future policies on use of blood products from COVID-19-positive donors

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

COVID-19 patients typically present with fever, nonproductive cough, dyspnea, myalgia, and/or fatigue. The main cause of death in COVID-19 patients is acute respiratory distress syndrome(ARDS). ARDS is caused by a cytokine storm that triggers an attack on the body by pro-inflammatory cytokines and chemokines, eventually resulting in multiple organ failure and death.

You may qualify if:

• \>\_18 years of age Surgical patients treated at Methodist Dallas Medical Center(MDMC)

You may not qualify if:

• \<18 years of age Prisoners Pregnant women

Sponsors & Collaborators

• Methodist Health System: lead

Study Sites (1)

Methodist Dallas Medical Center- Clinical Research Institute

Dallas, Texas, 75203, United States

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Jennifer Burris, Pharm D

  Methodist Health System

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 9, 2026
• First Posted: March 24, 2026
• Study Start: March 1, 2020
• Primary Completion: March 21, 2021
• Study Completion: June 25, 2025
• Last Updated: March 24, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: Not mentioned in protocol
• Access Criteria: Not mentioned in protocol

Locations

US (1)